Manages pain severe enough to require an opioid analgesic. ANDA 75977, held by Teva. Tramadol Hydrochloride.
As of Nov 16, 2026, ANDA 75977 (Tramadol Hydrochloride), held by Teva, was first approved by FDA on Jun 19, 2002, with 19 approved supplements and 0 published complete response letters.
Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including tramadol hydrochloride tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 19, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tramadol Hydrochloride50MG · tablet;oral | Tramadol Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 38REMS | Approved | None posted |
| Dec 22, 2025 | Supplement 36Labeling · Standard review | Approved | None posted |
| Dec 11, 2025 | Supplement 33Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Supplement 34REMS | Approved | None posted |
| Mar 22, 2024 | Supplement 29Manufacturing | Approved | None posted |
| Dec 18, 2023 | Supplement 32Labeling · Standard review | Approved | None posted |
| Dec 18, 2023 | Supplement 31Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 28Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 26Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 20Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 19Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 7, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Sep 18, 2018 | Supplement 17REMS | Approved | None posted |
| Nov 9, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 22, 2010 | Supplement 5Labeling | Approved | None posted |
| Apr 8, 2005 | Supplement 3Labeling | Approved | None posted |
| Oct 30, 2002 | Supplement 1Labeling | Approved | None posted |
| Jun 19, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters